Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2017 | Pages:
50 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Pipeline Review, H2 2017 Summary Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Pipeline Review, H2 2017, outlays comprehensive information on the Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Glucokinase is an enzyme that catalyzes the initial step in utilization of glucose by the beta-cell and liver at physiological glucose concentration. The role of GCK is to provide G6P for the synthesis of glycogen. Pancreatic glucokinase plays an important role in modulating insulin secretion. Hepatic glucokinase helps to facilitate the uptake and conversion of glucose by acting as an insulin-sensitive determinant of hepatic glucose usage. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 4 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders which include indications Type 2 Diabetes, Type 1 Diabetes (Juvenile Diabetes) and Obesity. Furthermore, this report also reviews key players involved in Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - The report reviews Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics and enlists all their major and minor projects - The report assesses Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Overview 6 Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Therapeutics Development 7 Products under Development by Stage of Development 7 Products under Development by Therapy Area 8 Products under Development by Indication 9 Products under Development by Companies 10 Products under Development by Universities/Institutes 12 Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Therapeutics Assessment 14 Assessment by Mechanism of Action 14 Assessment by Route of Administration 15 Assessment by Molecule Type 16 Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Companies Involved in Therapeutics Development 18 Amgen Inc 18 Eli Lilly and Co 18 Ligand Pharmaceuticals Inc 19 Merck & Co Inc 19 Poxel SA 20 Teijin Pharma Ltd 20 vTv Therapeutics Inc 20 Yuhan Corp 21 Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Drug Profiles 22 AM-9514 - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 Gene Therapy to Activate Glucokinase and Insulin for Diabetes and Obesity - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 LY-2608204 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 Sinogliatin - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 Small Molecules to Activate Glucokinase for Type 2 Diabetes - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Small Molecules to Activate Glucokinase for Type 2 Diabetes - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 Small Molecules to Activate Glucokinase for Type 2 Diabetes - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Small Molecules to Activate Glucokinase for Type 2 Diabetes - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 TMG-123 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 TTP-399 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 YH-GKA - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Dormant Products 37 Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Discontinued Products 38 Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Product Development Milestones 39 Featured News & Press Releases 39 Oct 17, 2016: Hua Medicine Announces First-Ever Successful Phase 2 Monotherapy Trial for New Class of Diabetes Drug 39 Aug 10, 2016: vTv Therapeutics Announces Positive Topline Results From Phase 2B Study Of Glucokinase Activator TTP399 In Type 2 Diabetes 39 Jun 14, 2016: vTv Therapeutics Presents Positive Results from a Pilot Study of its Glucokinase Activator at American Diabetes Association 76th Scientific Sessions 40 Apr 12, 2016: vTv Therapeutics Announces Presentation of its Diabetes Product Candidate TTP399 at the Keystone Symposia on New Therapeutics for Diabetes and Obesity 41 Feb 09, 2016: vTv Therapeutics Completes Enrollment of Phase 2b Trial Evaluating TTP399 for the Treatment of Type 2 Diabetes 41 Aug 13, 2015: Hua Medicine's GKA Diabetes Drug Demonstrates High Efficacy in 4-Week Phase 1c Trial 42 Jun 04, 2015: vTv Therapeutics Initiates Patient Dosing in the AGATA Study, a six Month Phase 2 Study Evaluating TTP399, a Liver-selective GlucoKinase Activator, for the Treatment of Type 2 Diabetes 42 Mar 10, 2015: Hua Medicine Files IND in US for its Novel GKA-based Diabetes Drug 43 Feb 09, 2015: Hua Medicine Announces Positive Phase 1b Results in Diabetes with 4th-Generation Glucokinase Activator, Shows Robust 24-hour Glucose Control 44 Mar 26, 2014: Hua Medicine tests glucokinase activator in Chinese diabetics 45 Mar 19, 2014: Hua Medicine's Novel Glucokinase Activator Reports Positive Phase 1a Data Demonstrating Robust Glucose Regulatory Hormone Modulation & Commences Phase 1b Trials in Diabetes Patients 46 Aug 14, 2013: First Liver-Selective Glucokinase Activator for Type 2 Diabetes Demonstrates Normalized HbA1c and No Hypoglycemia in Clinical Trial 47 Nov 29, 2012: Hua Medicine's Glucokinase Activator Passes Provincial FDA Inspections, Phase I Trial Likely To Be Launched In 2013 48 Nov 23, 2012: Hua Medicine Advances Diabetic Drug Towards Trial 48 Appendix 49 Methodology 49 Coverage 49 Secondary Research 49 Primary Research 49 Expert Panel Validation 49 Contact Us 49 Disclaimer 50
List of Tables
Number of Products under Development by Stage of Development, H2 2017 7 Number of Products under Development by Therapy Areas, H2 2017 8 Number of Products under Development by Indication, H2 2017 9 Number of Products under Development by Companies, H2 2017 10 Products under Development by Companies, H2 2017 11 Number of Products under Investigation by Universities/Institutes, H2 2017 12 Products under Investigation by Universities/Institutes, H2 2017 13 Number of Products by Stage and Mechanism of Actions, H2 2017 14 Number of Products by Stage and Route of Administration, H2 2017 15 Number of Products by Stage and Molecule Type, H2 2017 17 Pipeline by Amgen Inc, H2 2017 18 Pipeline by Eli Lilly and Co, H2 2017 18 Pipeline by Ligand Pharmaceuticals Inc, H2 2017 19 Pipeline by Merck & Co Inc, H2 2017 19 Pipeline by Poxel SA, H2 2017 20 Pipeline by Teijin Pharma Ltd, H2 2017 20 Pipeline by vTv Therapeutics Inc, H2 2017 21 Pipeline by Yuhan Corp, H2 2017 21 Dormant Projects, H2 2017 37 Discontinued Products, H2 2017 38
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
